Loading organizations...
Based in Bologna, Italy, CellPly develops analytical tools that utilize microfluidics, robotics, artificial intelligence, and biology to streamline the research, development, and quality control of cancer immunotherapies and cell therapies. The biotechnology company provides biopharmaceutical firms, clinical facilities, and research institutes with an automated platform that assesses the efficacy of cellular oncology treatments by evaluating individual cells. To support its ongoing commercialization efforts and a planned strategic expansion into the North American market, the enterprise has secured over €11 million in total funding through equity investments and research grants. This accumulated capital includes a €3.6 million financing round closed in September 2023, which followed previous financial backing from prominent institutional investors such as Italian Angels for Growth, LIFTT, and Indaco. CellPly was established as a biotechnology startup in 2013 by Massimo Bocchi and Roberto Guerrieri.
CellPly has raised $6.6M across 2 funding rounds.
CellPly has raised $6.6M in total across 2 funding rounds.
CellPly has raised $6.6M across 2 funding rounds. Most recently, it raised $3.8M Other Equity in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 2, 2023 | $3.8M Venture Round | LIFTT, Recomec, Schia Ventures | — | Announced |
| Mar 20, 2014 | $2.8M Seed | Atlante Seed | Italian Angels For Growth, Zernike Meta Ventures | Announced |
CellPly has raised $6.6M in total across 2 funding rounds.
CellPly's investors include LIFTT, Recomec, Schia Ventures, Atlante Seed, Italian Angels for Growth, Zernike Meta Ventures.
